Research & Trial Information


Protocol #: AFT-39

Cancer Type: Cancer Control

Inclusion Criteria:

  1. Adults (21+) with advanced/metastatic cancer of any type (EXCEPT leukemia or indolent [slow growing] lymphoma)

2. Receiving outpatient systemic cancer treatment for non-curative/palliative intent, including chemotherapy, targeted therapy, or immunotherapy.

3. Enrolled at any point in their treatment trajectory, meaning during any line of treatment, and at any point during a course or cycle of treatment.

Exclusion Criteria:

  1. Cognitive deficits that would preclude understanding of consent form and/or questionnaires.

2. Current participation in a therapeutic clinical trial (because these often involve PRO questionnaires and intensive monitoring).

3. Patients being treated with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer; primary curative therapy for testis cancer or lymphoma).

4. Receiving hormonal therapy only (e.g., tamoxifen or aromatase inhibitors in breast cancer; androgen deprivation therapy in prostate cancer; or octreotide in neuroendocrine cancers; ibrance/palbociclib).

5. Indolent lymphomas (due to their prolonged time courses that may be minimally symptomatic).

6. Leukemias (time courses inconsistent with other tumor types in chronic and acute leukemias).


Research & Trial Information


Protocol #: EAQ162CD

Cancer Type: Cancer Control GI

Eligibility Criteria for Patient Participants:

  1. Age ≥ 18 years.

2. Patients must have a life expectancy of ≥ 24 months.

3. ECOG PS 0-3.

4. Patients must have a newly diagnosed colon or rectal cancer (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) within 60 days of registration and have not yet received radiation or chemotherapy.

5. Patients must have Stage I, II, or III disease at the time of enrollment and will be treated with curative-intent. This can be defined either clinically or pathologically if they have already undergone surgery. For staging of both colon and rectal cancer, the definition of stage I-III is based on the seventh edition (2010) or an updated version of the TNM staging system.

6. Patients are not eligible if they are already enrolled on a treatment clinical trial at the time of registration. They can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period.

7. Patients who choose to not receive radiation and/or chemotherapy after a curative-intent surgery are eligible to participate.

8. Patients with a history of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the last 3 years are not eligible because it is possible that their employment and burden due to cancer care may be impacted by their previous malignancy and therefore add heterogeneity to the study.

9. Patients must be able to complete questionnaires in English.



Research & Trial Information


Protocol#: SWOG – S1605

Cancer Type: GU Bladder


  1. Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration. The carcinoma must be Stage T1 High-Grade, Stage CIS, or Stage Ta High-Grade.
  2. Patients with mixed urothelial carcinoma and a glandular and/or squamous component will be eligible for the trial, but the presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, will make a patient ineligible.
  3. Patients must have had all visible tumor resected completely within 60 days prior to registration. CIS disease is not expected to be completely excised. All patients must have tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission. Failure to submit these materials will make the patient ineligible for this study.

Genesys Hurley Cancer Institute

302 Kensington Avenue
Flint, MI 48503

810-762-8226 | 888-762-8675

Genesys Health System
Hurley Medical Center
Michigan Cancer Consortium


Ⓒ 2019 Genesys Hurley Cancer Institute | All Rights Reserved.